ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 669,31
1,16%
DAX
18 001,60
0,54%
Brent Oil
83,185
-0,53%
Bitcoin
61 979,30
4,83%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Antares Pharma Inc (ATRS)

  7. Antares Pharma Inc (ATRS) Actualités

ATRS

Antares Pharma (ATRS)

Antares Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ATRS
DateHeureSourceTitreSymboleSociété
26/05/202223h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRSAntares Pharma Inc
24/05/202222h50Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ATRSAntares Pharma Inc
24/05/202222h32Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ATRSAntares Pharma Inc
24/05/202222h23Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRSAntares Pharma Inc
24/05/202215h08Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ATRSAntares Pharma Inc
24/05/202212h11Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ATRSAntares Pharma Inc
13/05/202222h46Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:ATRSAntares Pharma Inc
12/05/202214h00PR Newswire (US)Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares PharmaNASDAQ:ATRSAntares Pharma Inc
10/05/202223h28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ATRSAntares Pharma Inc
06/05/202218h10Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ATRSAntares Pharma Inc
02/05/202222h50Business WireANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRSNASDAQ:ATRSAntares Pharma Inc
02/05/202212h03Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ATRSAntares Pharma Inc
29/04/202223h56Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ATRSAntares Pharma Inc
26/04/202213h17Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:ATRSAntares Pharma Inc
26/04/202213h02Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ATRSAntares Pharma Inc
14/04/202212h10Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ATRSAntares Pharma Inc
13/04/202212h00PR Newswire (US)Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery LeaderNASDAQ:ATRSAntares Pharma Inc
29/03/202213h00GlobeNewswire Inc.Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyNASDAQ:ATRSAntares Pharma Inc
07/03/202212h16TipRanksAnalysts Are Bullish on Top Healthcare Stocks: Aclaris Therapeutics (ACRS), Antares Pharma (ATRS)NASDAQ:ATRSAntares Pharma Inc
03/03/202213h00GlobeNewswire Inc.Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating ResultsNASDAQ:ATRSAntares Pharma Inc
28/02/202214h30GlobeNewswire Inc.Antares Pharma to Present at the Cowen 42nd Annual Healthcare ConferenceNASDAQ:ATRSAntares Pharma Inc
17/02/202214h30GlobeNewswire Inc.Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating ResultsNASDAQ:ATRSAntares Pharma Inc
03/02/202214h00GlobeNewswire Inc.Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®NASDAQ:ATRSAntares Pharma Inc
01/02/202223h16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ATRSAntares Pharma Inc
18/01/202213h30GlobeNewswire Inc.Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis RescueNASDAQ:ATRSAntares Pharma Inc
12/01/202215h06Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:ATRSAntares Pharma Inc
12/01/202214h30GlobeNewswire Inc.Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human ResourcesNASDAQ:ATRSAntares Pharma Inc
11/01/202213h30GlobeNewswire Inc.Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis RescueNASDAQ:ATRSAntares Pharma Inc
17/12/202113h53GlobeNewswire Inc.MedMira strengthen its Board with New AppointmentNASDAQ:ATRSAntares Pharma Inc
15/12/202123h58GlobeNewswire Inc.Antares Pharma Announces Divestiture of Otrexup®NASDAQ:ATRSAntares Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:ATRS

Dernières Valeurs Consultées

EU
VK
Vallourec
COIN
BTCUSD
Bitcoin
NASDAQ
GOOGL
Alphabet
EU
DG
Vinci
EU
CS
Axa
EU
AI
Air Liquide
EU
ORA
Orange
EU
ML
Michelin
EU
GLE
Societe Generale
SPI
SP500
S&P 500
EU
RNO
Renault
NASDAQ
AAPL
Apple
NYSE
MRK
Merck
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés